Zevra Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Zevra Therapeutics has a total shareholder equity of $133.2M and total debt of $61.3M, which brings its debt-to-equity ratio to 46%. Its total assets and total liabilities are $270.1M and $137.0M respectively.
Key information
46.04%
Debt to equity ratio
US$61.31m
Debt
| Interest coverage ratio | n/a |
| Cash | US$199.51m |
| Equity | US$133.17m |
| Total liabilities | US$136.95m |
| Total assets | US$270.12m |
Recent financial health updates
Recent updates
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 08
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Nov 03What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Sep 08Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 10Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
May 22
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Mar 10Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17Financial Position Analysis
Short Term Liabilities: ZVRA's short term assets ($225.1M) exceed its short term liabilities ($26.1M).
Long Term Liabilities: ZVRA's short term assets ($225.1M) exceed its long term liabilities ($110.8M).
Debt to Equity History and Analysis
Debt Level: ZVRA has more cash than its total debt.
Reducing Debt: ZVRA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: ZVRA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ZVRA's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 11:36 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zevra Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Dewey Steadman | Canaccord Genuity |
| Louise Chen | Cantor Fitzgerald & Co. |